d. Add to the end of paragraph (c) the phrase "also, except for an appeal related to records originating in the Office of the Inspector General".

The revision reads as follows:

§ 1212.701  Associate Deputy Administrator.

* * * * *

§ 1212.702 through 1212.706  [Redesignated as §§ 1212.703 through 1212.707]

16. Redesignate §§ 1212.702 through 1212.706 as §§ 1212.703 through 1212.707 and add a new § 1212.702 to read as follows:

§ 1212.702  The Inspector General.

The Inspector General is responsible for:

(a) Making final Agency determinations on appeals related to records originating with the Office of the Inspector General (§ 1212.400), and

(b) Authorizing an extension for making a final determination on an appeal related to records originating with the Office of the Inspector General (§ 1212.400(e)).

17. In newly redesignated § 1212.703:

a. Revise the section heading;

b. In paragraph (a) introductory text, remove the word "Associate Administrator for Management Systems and Facilities" and add in its place "NASA Chief Information Officer";

c. In paragraph (b):

i. Remove the phrase "Associate Administrator for Management Systems and Facilities" and add in its place "Chief Information Officer";

ii. Remove the words "Privacy Officer" and add in its place "NASA Privacy Act Officer"; and

iii. Remove the word "or" and the phrase "reporting directly to the Associate Administrator for Management Systems and Facilities".

The revision reads as follows:

§ 1212.703  NASA Chief Information Officer.

* * * * *

18. In newly redesignated § 1212.704:

a. Revise the section heading;

b. In paragraph (a) introductory text, remove the word "Installations" and add in its place "Centers";

c. In paragraph (a)(3), remove the reference "§ 1212.203(g)" and add in its place "§ 1212.203(f)";

d. In paragraph (a)(4), remove the reference "§ 1212.704a(4) and (5)" and add in its place "§ 1212.704a(4) and (5)"; and

e. Add paragraph (a)(5) and (f).

f. Remove and reserve paragraph (b).

The revision reads as follows:

§ 1212.704  Headquarters and Field Centers or Component Facilities.

(a) * * *

(5) Establish a position of Center Privacy Manager to assist in carrying out the responsibilities listed in this section.

* * * * *

19. In newly redesignated § 1212.705:

a. Revise paragraph (a)(1);

b. In paragraph (a)(3), remove the word "Assistant" and add in its place "Associate";

c. In paragraph (a)(7), remove the reference "§ 1212.203(g)(1) through (12)" and add in its place "§ 1212.203(f)(1) through (12)";

d. In paragraph (a)(12), remove "14 CFR" and add in its place "§ 1212.704" and add the words "of this part" after "1212.203";

e. In paragraph (c), remove the word "Installation" and add in its place "Center" and remove the reference "§ 1212.703(a)(4) and (b)" and add in its place "§ 1212.704(a)(4) and (5)"

§ 1212.705  System manager.

(a) * * *


* * * * *

Charles F. Bolden, Jr., Administrator.

[FR Doc. 2012–23645 Filed 10–3–12; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 510, 520, and 558

[Docket No. FDA–2012–N–0002]

New Animal Drugs; Change of Sponsor’s Address; Monensin; Spinosad; Tilimicosin

AGENCY: Food and Drug Administration, HHSS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NDAs) during August 2012 and to reflect a change of sponsor’s address for Baxter Healthcare Corp. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable.

DATES: This rule is effective October 4, 2012.

FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine (HFV–6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240–276–9019, george.haibel@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: FDA is amending the animal drug regulations to reflect original and supplemental approval actions during August 2012, as listed in table 1 of this document. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the Center for Veterinary Medicine (HFV–6) FOIA Electronic Reading Room. FOI Summaries may be found listed by application number at: http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/default.htm. Environmental assessments and findings of no significant impact may be found listed by the established name of the active pharmaceutical ingredient at: http://www.fda.gov/AnimalVeterinary/DevelopmentApprovalProcess/EnvironmentalAssessments/ucm306036.htm.

Also, Baxter Healthcare Corp., 95 Spring St., New Providence, NJ 07974, has informed FDA of a change of address to One Baxter Pkwy., Deerfield, IL 60015. Accordingly, the Agency is amending the regulations in 21 CFR 510.600(c) to reflect this change.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects

21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

21 CFR Part 520

Animal drugs.

21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, and 558 are amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:


2. In §510.600, in the table in paragraph (c)(1), revise the entry for “Baxter Healthcare Corp.”; and in the table in paragraph (c)(2), revise the entry for “010019” to read as follows:

§510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

(1) * * *

Firm name and address Drug labeler code

Baxter Healthcare Corp., One Baxter Pkwy., Deerfield, IL 60015. 010019

(2) * * *

Drug labeler code Firm name and address

010019 ........ Baxter Healthcare Corp., One Baxter Pkwy., Deerfield, IL 60015.

PART 520—ORAL DOSAGE FORM

New animal drugs

3. The authority citation for 21 CFR part 520 continues to read as follows:


4. Revise §520.2130 to read as follows:

§520.2130 Spinosad.

(a) Specifications. Each chewable tablet contains 90, 140, 270, 560, 810, or 1620 milligrams (mg) spinosad.

(b) Sponsor. See No. 0000986 in § 510.600 of this chapter.

(c) Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) Conditions of use—(1) Dogs—(i) Amount. Administer tablets once a month at a recommended minimum dosage of 13.5 mg per pound (30 mg per kilogram) of body weight.

(ii) Indications for use. To kill fleas and for the prevention and treatment of flea infestations (Ctenocephalides felis) for 1 month on dogs and puppies 14 weeks of age and older and 3.3 pounds of body weight or greater.

(2) Cats—(i) Amount. Administer tablets once a month at a minimum dosage of 22.5 mg per pound (50 mg per kilogram) of body weight.

(ii) Indications for use. To kill fleas and for the prevention and treatment of flea infestations (C. felis) for 1 month on cats and kittens 14 weeks of age and older and 2 pounds of body weight or greater.

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

5. The authority citation for 21 CFR part 558 continues to read as follows:


6. In §558.355, redesignate paragraph (f)(8)(iv) as paragraph (f)(8)(v); and add new paragraph (f)(8)(iv) to read as follows:

§558.355 Monensin.

* * * * *

(f) * * *

(8) * * *

(iv) Tilmicosin alone or in combination as in §558.618.

* * * * *

7. In §558.618, remove and reserve paragraph (e); and revise paragraph (e) to read as follows:
§ 558.618 Tilmicosin.

(e) * * *

(1) Swine—

<table>
<thead>
<tr>
<th>Tilmicosin phosphate in grams/ton</th>
<th>Combination in grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 181 to 363</td>
<td></td>
<td></td>
<td>Feed continuously as the sole ration for 21-day period, beginning approximately 7 days before an anticipated disease outbreak. The safety of tilmicosin has not been established in male swine intended for breeding purposes. Swine intended for human consumption must not be slaughtered within 7 days of the last treatment with this drug product.</td>
<td>000986</td>
</tr>
<tr>
<td>(ii) [Reserved]</td>
<td></td>
<td></td>
<td></td>
<td>000986</td>
</tr>
</tbody>
</table>

(2) Cattle—

<table>
<thead>
<tr>
<th>Tilmicosin phosphate in grams/ton</th>
<th>Combination in grams/ton</th>
<th>Indications for use</th>
<th>Limitations</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) 568 to 757</td>
<td></td>
<td>Beef and nonlactating dairy cattle: For the control of bovine respiratory disease (BRD) associated with <em>Mannheimia haemolytica</em>, <em>Pasteurella multocida</em>, and <em>Histophilus somni</em> in groups of beef and nonlactating dairy cattle, where active BRD has been diagnosed in at least 10 percent of the animals in the group.</td>
<td>Feed continuously for 14 days to provide 12.5 milligrams/kilogram/head/day. The safety of tilmicosin has not been established in cattle intended for breeding purposes. This drug product is not approved for use in female dairy cattle 20 months of age or older. Use in these cattle may cause drug residues in milk. This drug product is not approved for use in calves intended to be processed for veal. A withdrawal period has not been established in pre-ruminating calves. Cattle intended for human consumption must not be slaughtered within 28 days of the last treatment with this drug product.</td>
<td>000986</td>
</tr>
<tr>
<td>(ii) 568 to 757</td>
<td>Monensin, 5 to 40.</td>
<td>Cattle fed in confinement for slaughter: For improved feed efficiency; and for the control of bovine respiratory disease (BRD) associated with <em>Mannheimia haemolytica</em>, <em>Pasteurella multocida</em>, and <em>Histophilus somni</em> in groups of cattle fed in confinement for slaughter, where active BRD has been diagnosed in at least 10 percent of the animals in the group.</td>
<td>Feed continuously for 14 days to provide 12.5 milligrams/kilogram/head/day. The safety of tilmicosin has not been established in cattle intended for breeding purposes. This drug product is not approved for use in female dairy cattle 20 months of age or older. Use in these cattle may cause drug residues in milk. This drug product is not approved for use in calves intended to be processed for veal. A withdrawal period has not been established in pre-ruminating calves. Cattle intended for human consumption must not be slaughtered within 28 days of the last treatment with this drug product. See §558.355(d) of this chapter.</td>
<td>000986</td>
</tr>
<tr>
<td>(iii) 568 to 757</td>
<td>Monensin, 10 to 40.</td>
<td>Cattle fed in confinement for slaughter: For prevention and control of coccidiosis due to <em>Eimeria bovis</em> and <em>E. zuernii</em>; and for the control of bovine respiratory disease (BRD) associated with <em>Mannheimia haemolytica</em>, <em>Pasteurella multocida</em>, and <em>Histophilus somni</em> in groups of cattle fed in confinement for slaughter, where active BRD has been diagnosed in at least 10 percent of the animals in the group.</td>
<td>Feed continuously for 14 days to provide 12.5 milligrams tilmicosin/kilogram/head/day. The safety of tilmicosin has not been established in cattle intended for breeding purposes. This drug product is not approved for use in female dairy cattle 20 months of age or older. Use in these cattle may cause drug residues in milk. This drug product is not approved for use in calves intended to be processed for veal. A withdrawal period has not been established in pre-ruminating calves. Cattle intended for human consumption must not be slaughtered within 28 days of the last treatment with this drug product. See §558.355(d) of this chapter.</td>
<td>000986</td>
</tr>
</tbody>
</table>


Bernadette Dunham,
Director, Center for Veterinary Medicine.

[FR Doc. 2012–24475 Filed 10–3–12; 8:45 am]

BILLING CODE 4160–01–P